Tagista, tablets 24 mg 30 pcs

Betahistine improves microcirculation of the labyrinth, it is used in pathology of the vestibular apparatus.

The drug acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

With direct agonist effect on histamine H1-receptors of inner ear vessels and indirectly through effect on histamine H3-receptors it improves microcirculation and capillary permeability

and normalizes endolymph pressure in labyrinth and cochlea. At the same time, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of histamine H3-receptor nuclei of the vestibular nerve. It normalizes conduction in the neurons of the vestibular nuclei at the level of the brainstem.

The clinical manifestation of the above properties is reduction of the frequency and intensity of dizziness, decrease of tinnitus, improvement of hearing in case of its reduction.

Indications

Treatment and prevention of vestibular vertigo of various origins;
Syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
Meniere’s disease or syndrome.

Pharmacological effect

Betahistine improves microcirculation of the labyrinth and is used for pathologies of the vestibular apparatus.

The drug acts mainly on histamine H1 and H3 receptors in the inner ear and vestibular nuclei of the central nervous system.

Through a direct agonistic effect on histamine H1 receptors in the vessels of the inner ear, as well as indirectly through an effect on histamine H3 receptors, it improves microcirculation and permeability

capillaries, normalizes endolymph pressure in the labyrinth and cochlea. At the same time, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of histamine H3 receptors in the nuclei of the vestibular nerve. Normalizes conductivity in the neurons of the vestibular nuclei at the level of the brain stem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.

Special instructions

Effect on the ability to drive a car and other mechanisms

Betahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities requiring rapid psychomotor reactions.

Active ingredient

Betahistine

Composition

1 tablet contains

Active ingredient:

Betahistine dihydrochloride 24.0 mg;

Excipients:

Microcrystalline cellulose – 64.25 mg,

Povidone (kollidon 25) – 27.0 mg

Potato starch – 60.0 mg,

Citric acid – 6.0 mg,

Silicon dioxide colloidal (Aerosil), – 9.0 mg,

Talc – /8.4 mg,

Magnesium stearate – /1.35 mg.

Contraindications

hypersensitivity to any of the components of the drug:

age under 18 years (due to lack of data);

pregnancy and lactation (due to lack of data).

With caution
peptic ulcer of the stomach or duodenum (including a history), pheochromocytoma, bronchial asthma. These patients should be monitored regularly during treatment.

Side Effects

Gastrointestinal disorders. the appearance of hypersensitivity reactions on the skin (rash, itching, urticaria), Quincke’s edema.

Interaction

There are no known cases of interaction or incompatibility with other drugs.

Overdose

Symptoms:

nausea, vomiting, cramps.

Treatment:

gastric lavage, intake of activated carbon, symptomatic therapy.

Prescribing

Histamine reparative

Complete set of goods

Tablets 24 mg. 10 or 30 tablets in blister packs.

30 tablets in a polymer jar.

3 blister packs of 10 tablets each, 1, 2 or 3 blister packs of 30 tablets each, or a polymer jar along with instructions for use in a cardboard pack.

Functional features

Absorbed quickly, binding to plasma proteins is low.

Time to reach maximum concentration in blood plasma – 3 hours

Almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours.

The half-life is 3 – 4 hours.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25°C. Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date stated on the package.

Manufacturer

Hemofarm LLC, Russia